Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 5/20 | 0.77 |
| ▸ | USP2 | O75604 | 3/20 | 0.77 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.77 |
| ▸ | RECQL | P46063 | 2/20 | 0.77 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.77 |
| ▸ | EGFR | P00533 | 1/20 | 0.77 |
| ▸ | LCK | P06239 | 1/20 | 0.77 |
| ▸ | FYN | P06241 | 1/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.77 |
| ▸ | HTR2A | P28223 | 1/20 | 0.77 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.77 |
| ▸ | PKM | P14618 | 3/20 | 0.56 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | XIAP | P98170 | 1/20 | 0.56 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29508389 | 1.00 | SLC7A5 (0.77) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| SCHEMBL338068 | 1.00 | SLC7A5 (0.77) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| SCHEMBL29364864 | 0.94 | SLC7A5 (0.69) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| SCHEMBL9924695 | 0.94 | SLC7A5 (0.69) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| SCHEMBL13588692 | 0.91 | SLC7A5 (0.65) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| Levodopa SCHEMBL22655 | 0.87 | SLC7A5 (1.00) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| Levodopa SCHEMBL704089 | 0.87 | SLC7A5 (1.00) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| Levodopa SCHEMBL29975814 | 0.87 | SLC7A5 (1.00) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| Levodopa SCHEMBL20582239 | 0.87 | SLC7A5 (1.00) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| Levodopa SCHEMBL11000382 | 0.87 | SLC7A5 (1.00) | SLC7A5USP2PTGS1KDM4EALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190100784-A1 | RNA ANALYSIS BY TOTAL HYDROLYSIS | CureVac SE (DE) | 2019-04-04 | — | — | US | claimed |
| EP-3423595-A1 | RNA ANALYSIS BY TOTAL HYDROLYSIS | CureVac AG (DE) | 2019-01-09 | — | — | EP | claimed |
| US-11920174-B2 | RNA analysis by total hydrolysis and quantification of released nucleosides | CureVac SE (DE) | 2024-03-05 | — | — | US | disclosed |
| US-20190100784-A1 | RNA ANALYSIS BY TOTAL HYDROLYSIS | CureVac SE (DE) | 2019-04-04 | — | — | US | disclosed |
| EP-3439683-A1 | IMMUNE SYSTEM MODULATION FOR PROPHYLAXIS AND TREATMENT OF DISEASES AND DISORDERS | Marpe Holdings, LLC (US) | 2019-02-13 | — | — | EP | disclosed |
| EP-3423595-A1 | RNA ANALYSIS BY TOTAL HYDROLYSIS | CureVac AG (DE) | 2019-01-09 | — | — | EP | disclosed |
| WO-2017176757-A1 | IMMUNE SYSTEM MODULATION FOR PROPHYLAXIS AND TREATMENT OF DISEASES AND DISORDERS | Marpe Holdings, LLC (US) | 2017-10-12 | — | — | WO | disclosed |
| US-20170283460-A1 | Immune System Modulation for Prophylaxis and Treatment of Diseases and Disorders | Marpe Holdings, LLC (US) | 2017-10-05 | — | — | US | disclosed |
| US-9340595-B2 | Crosslinking within coordination complexes | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2016-05-17 | — | — | US | disclosed |
| US-9328163-B2 | Post-translationally modified neurotrophin antibodies | INSTITUT PASTEUR (FR) | 2016-05-03 | — | — | US | disclosed |
| US-20140294724-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROTEINOPATHIES | INTELLECT NEUROSCIENCES, INC. (US) | 2014-10-02 | — | — | US | disclosed |
| US-20090297538-A1 | NEUROTOXIC OLIGOMERS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2009-12-03 | — | — | US | disclosed |
| US-7618634-B2 | Alzheimer's disease, Prkinson's disease, vision defects therapy; tyrosine crosslinked protein | PRANA BIOTECHNOLOGY LIMITED (AU) | 2009-11-17 | — | — | US | disclosed |
| EP-2046823-A1 | POST-TRANSLATIONALLY MODIFIED NEUROTROPHINS | Institut Pasteur (FR) | 2009-04-15 | — | — | EP | disclosed |
| EP-1668067-A4 | CROSSLINKING WITHIN COORDINATION COMPLEXES | UNIV UTAH RES FOUND (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2008012049-A1 | POST-TRANSLATIONALLY MODIFIED NEUROTROPHINS | INSTITUT PASTEUR (FR) | 2008-01-31 | — | — | WO | disclosed |
| EP-1882697-A1 | Post-translationally modified neurotrophins | INSTITUT PASTEUR (FR) | 2008-01-30 | — | — | EP | disclosed |
| EP-1668067-A2 | CROSSLINKING WITHIN COORDINATION COMPLEXES | The University of Utah Research Foundation (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005019421-A2 | CROSSLINKING WITHIN COORDINATION COMPLEXES | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20040013680-A1 | Neurotoxic oligomers | THE GENERAL HOSPITAL CORPORATION | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294724-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROTEINOPATHIES | CLN6, PSMG3, PSEN1 | SLC7A5 3719/4885USP2 1522/4885PTGS1 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.